Braveheart PLC (LON:BRH) has said its majority-owned investee company Pharm2Farm has switched manufacturing capacity to hand sanitiser gel in response to the coronavirus crisis.
In a statement, the group said production is currently 500 litres per day, with supplies sent to NHS fulfilment centres, regional NHS Clinical Commissioning Groups and other users.
Pharm2Farm has also started to test nano-copper particles in Personal Protection Equipment (PPE) used by NHS and care staff.
There is evidence that the coronavirus cannot survive long on copper and Pharma2Farm is testing to see if copper nanofibres can be woven into sheets of material. These anti-viral sheets could be laminated into surgical masks and embedded into other PPE to enhance protection.
Nano anti-viral fabrics might also be used in filtration systems to help prevent the spread of the airborne virus.
Braveheart said another investee company Kirkstall (64.5%-owned) is using it’s in vitro cell culture technology, “QuasiVivo”, to help research into the study of respiratory disease and a faster route than using animal testing to develop a vaccine.
Animal-based research has been severely disrupted by coronavirus restrictions and Kirkstall believes these conditions will provide an opportunity for a major re-appraisal of whether animal testing methods are appropriate for human-relevant research.
QuasiVivo is an easy to use replacement for animals in research, believes Kirkstall.
Elsewhere, Phasefocus Holdings instruments are now being distributed in China again, while 100% owned Paraytec is working with major biotech companies to look as adapting ‘virus-like particles’ to deliver new gene therapy drugs, Braveheart added.